asal High-Flow Therapy to treat COPD exacerbations: a matter of monitoring and controlling settings?

Phase 3

Recruiting

• Conditions: Emphysema; Bronchitis; 10006436

• Registration Number: NL-OMON52864
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 158

Inclusion Criteria

• History of COPD Global Initiative of Obstructive Lung Diseases (GOLD) stage
II to IV (FEV1< 80% of predicted with an FEV1/forced vital capacity (FVC) ratio
<70), with a history of at least 10 pack years smoking.
• At least 1 COPD exacerbation in the year prior to the index hospital
admission (exacerbation defined as worsening of pulmonary symptoms requiring
oral steroids and/or antibiotics and/or hospital admission)
• Being admitted to the hospital with a COPD exacerbation
• Written informed consent is obtained

Exclusion Criteria

• No lung function data available, • The presence of another acute condition
(e.g. pneumonia, acute congestive heart failure, pulmonary embolus) explaining
or significantly contributing to the index admission, • Inability to comply
with the tests, • The presence of another chronic lung disease (e.g. asthma,
restrictive lung disease).

• Already on non-invasive ventilation or nasal high flow therapy (at home
or during the exacerbation)

Study & Design

• Study Type: Interventional
• Study Design: Not specified